Welcome to the e-CCO Library!

P407: Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

P.M. Hellström1*, M. Lonnkvist2, H.O. Diaz Tartera1, R. Befrits2, M. Holst3

Created: Thursday, 21 February 2019, 9:14 AM
P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Orlandini B., Dragoni G., Bagnoli S., Deiana S., Macrì G., Rogai F.

Created: Wednesday, 20 February 2019, 10:36 AM
P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Yarur*1, L. Bixuan1, P. Deepak2, A. Khatiwada2, G. Christophi2, M. Ciorba2, R. Ungaro3, M. Fenster3, C. Dimopoulos3, G. Syal4, R. Hirten3, J-F. Colombel3, C. Ha4, R. Weisshof5, J. Pekow5, A. Patel6, P. Beniwal-Patel1, B. Cohen3

Created: Friday, 22 February 2019, 9:41 AM
P407: Thiopurines: use them or lose them? Results of an international survey
Year: 2021
Source: ECCO'21 Virtual
Authors: Sousa, P.C.(1);Ministro, P.(2);Armuzzi, A.(3,4);Dignass, A.(5);Høivik, M.L.(6);Magro, F.(7,8,9);
Created: Wednesday, 2 June 2021, 4:12 PM
P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Orfanoudaki1, M. Gazouli2, K. Foteinogiannopoulou1, E. Theodoraki1, E. Legaki2, I. Koutroubakis1

Created: Thursday, 30 January 2020, 10:12 AM
P408: Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
Year: 2021
Source: ECCO'21 Virtual
Authors: Doherty, J.(1);Varley, R.(1);Healy, M.(2);Dunne, C.(1);Mac Carthy, F.(1);McKiernan, S.(1);Hartery, K.(1);Kevans, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P408: Are pharmacokinetics more unfavourable in inflammatory bowel disease patients aged over 60 years?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Rinaldi1, N. Williet*2, E. Del tedesco2, c. Jarlot3, J. M. Phelip2, s. Paul4, X. Roblin3

Created: Friday, 22 February 2019, 9:49 AM
P408: Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kolar, M.(1);Kastylova, K.(1);Lukas, M.(1);Duricova, D.(1);Hruba, V.(1);Machkova, N.(1);Cerna, K.(1);Jirsa, J.(1);Kubickova, K.(1);Vojtechova, G.(1);Lukás, M.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P408: Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Shields, S.(1);Dunlop, A.(2);Gerasimidis, K.(3);Nichols, B.(3);Galloway, P.(2);Macdonald, J.(1);Hansen, R.(4);Seenan, J.P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P408: Intestinal failure in Crohn’s disease: A case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Soop1*, A. Bond2, E. Nixon2, A. Teubner1, A. Abraham1, G. Carlson1, S. Lal2

Created: Thursday, 21 February 2019, 9:14 AM
P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in Norway
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lerang F., Henriksen M., Jelsness-Jørgensen L.-P.

Created: Wednesday, 20 February 2019, 10:36 AM
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. van Hoeve*1,2, E. Dreesen3, I. Hoffman1, M. Ferrante2,4, A. Gils3, S. Vermeire2,4

Created: Friday, 22 February 2019, 9:41 AM
P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. WANN1, R. Norris1, R. Williams2, C. Basnayake1, M. Lust1, E. Wright1, M. Kamm1, W. Connell1, A. Thompson1, N. Ding1

Created: Thursday, 30 January 2020, 10:12 AM
P409: FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial
Year: 2022
Source: ECCO'22
Authors: Quraishi, M.N.(1);Quince, C.(2);Hewitt, C.(3);Beggs, A.(4);Gerasimidis , K.(5);Sharma, N.(1);Hawkey, P.(6);Oo, Y.(7);Ives, N.(3);Manzoor, S.(8);Loman, N.(6);Hansen, R.(9);Hart, A.(10);Gaya, D.(11);Iqbal, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
P409: Impact of biological therapy in postoperative morbidity in elective surgical resections in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. G. Kotze*1, M. P. Saab1, B. Saab1, L. M. S. Kotze1, M. Olandoski2, L. V. Pinheiro3, C. A. R. Martinez3, M. L. S. Ayrizono3, D. O. Magro3, C. S. R. Coy3

Created: Friday, 22 February 2019, 9:49 AM
P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Suzuki1*, T. Hagiwara2, M. Kobayashi2, K. Morita2, T. Shimamoto2, T. Hibi3

Created: Thursday, 21 February 2019, 9:14 AM
P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Levine A.*1, Yerushalmi B.2, Kori M.3, Broide E.4, Mozer-Glassberg Y.5, Shaoul R.6, Kolho K.-L.7, Shteyer E.8, Shamaly H.9, Ledder O.10, Cohen S.11, Peleg S.12, Sarbagili-Shabat C.1, Focht G.10, Shachmon E.10, Boaz M.13, On A.14, Turner D.10

Created: Wednesday, 20 February 2019, 10:36 AM
P409: Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
Year: 2021
Source: ECCO'21 Virtual
Authors: D’Haens, G.R.(1);Dubinsky, M.C.(2);Regueiro, M.(3);Santana, G.O.(4);Torres, J.(5);Kulisek, N.(6);Gardiner, S.(7);Mundayat, R.(7);Paulissen, J.(7);Lawendy, N.(6);Su, C.(6);Modesto, I.(7);Sandborn, W.J.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Gonczi*1, A. Ilias1, K. Szanto2, Z. Kurti1, P. A. Golovics3, K. Farkas2, E. Schafer3, Z. Szepes2, B. Szalay4, A. Vincze5, T. Szamosi3, T. Molnar2, P. Lakatos6

Created: Friday, 22 February 2019, 9:41 AM
P409: Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluation
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Moulton, C.(1)*;Avery, P.(2);Hart, A.(3);
Created: Friday, 14 July 2023, 11:05 AM